Mixed Smallpox Vaccine Stockpile Could Complicate Mass Vaccination, Bavarian Nordic Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Smallpox vaccine candidate Imvamune has not demonstrated the potential for serious adverse events associated with Wyeth's Dryvax or Acambis/Baxter's ACAM-2000, VP-R&D Paul Chaplin, PhD, says in interview with "The Blue Sheet."